Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.
Abstract: A resin composition that exhibits excellent moldability and excellent mechanical strength, and may suitably be used to produce a resin product that suppresses elution from the inner wall thereof is disclosed. In particular, a medical or biochemical resin composition that prevents adsorption of proteins, polypeptides, and peptides, and exhibits biocompatibility, antithrombogenicity, elution resistance, and moldability (e.g., injection moldability), and a resin molded product are disclosed. The medical or biochemical resin composition includes a polypropylene-based resin, and a hydrogenated derivative of a block copolymer shown by X-Y (wherein X represents s a polymer block immiscible with the polypropylene-based resin, and Y represents an elastomer polymer block of a conjugated diene), the polypropylene-based resin having a content of an antioxidant of 1 mass % or less and a content of an additive of 0.5 mass % or less, the additive being used to disperse the antioxidant in the polypropylene-based resin.
Abstract: Disclosed herein is an RNA virus infection inhibitor that is capable of effectively inhibiting humans from being infected with RNA viruses to prevent the occurrence of symptoms or, even when symptoms occur, to relieve the symptoms and is less likely to cause unexpected discoloration or discoloration under normal service conditions. The RNA virus infection inhibitor comprises an RNA virus infection-inhibiting compound comprising a linear polymer having, in its side chain, at least one of substituents having structural formulas represented by general formulas (1) to (3).
Abstract: The invention relates to graftable polymers comprising biologically active agents and the use of such polymers in the manufacture of shaped articles, such as implantable medical devices and catheters. The graftable polymers are covalently grafted to a surface via one or more grafting moieties incorporated into the pharmaceutically-active graftable polymer. The coated articles of the invention can further comprise tie-coats, and the ratio of polymer:tie coat can be used to adjust the rate of drug elution.
Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.
Type:
Grant
Filed:
September 26, 2007
Date of Patent:
April 23, 2013
Assignee:
Genzyme Corporation
Inventors:
Pradeep K. Dhal, David J. Harris, Stephen Randall Holmes-Farley, Chad C. Huval, Vitaly Nivorozhkin, Bruce Shutts
Abstract: A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided.
Abstract: The present invention relates to combinations of the pyrion compounds sodium pyrithione and 1-hydroxy-2-pyridinone, and polyethyleneimines (PEI) which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of a pyrion compound selected from sodium pyrithione and 1-hydroxy-2-pyridinone together with polyethyleneimines; in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, viruses, and the like.
Type:
Application
Filed:
June 29, 2011
Publication date:
April 18, 2013
Applicant:
JANSSEN PHARMACEUTICA NV
Inventors:
Dany Leopold Jozefien Bylemans, Miguel F.C. De Bolle
Abstract: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.
Type:
Grant
Filed:
August 10, 2007
Date of Patent:
April 16, 2013
Assignee:
Starpharma Pty Ltd
Inventors:
Guy Yeoman Krippner, Charlotte Claire Williams, Brian Devlin Kelly, Scott Andrew Henderson, Zemin Wu, Pasquale Razzino
Abstract: The disclosure concerns altering the mechanical and/or chemical property of a body tissue, particularly an ocular tissue. In specific cases, it concerns altering or stabilizing the shape of the cornea, such as in a subject suffering or at risk for ectasia or keratoconus. In other specific cases, it concerns strengthening the sclera in a subject suffering or at risk for myopia. The invention employs light irradiation of a photoactivatable compound, such as one that applies crosslinking to the tissue, for example.
Type:
Grant
Filed:
October 24, 2007
Date of Patent:
April 9, 2013
Assignees:
The Regents of the University of California, California Institute of Technology
Inventors:
Matthew S. Mattson, Julia A. Kornfield, Daniel M. Schwartz, Robert K. Maloney, Robert H. Grubbs
Abstract: The invention relates to a composition containing, preferably in a physiologically acceptable medium, at least one xanthine base or a plant extract containing it, at least one polyurethane powder, and at least one non-ionic dimethicone copolyol. The invention also relates to a cosmetic method for combating cellulite and/or “orange-peel” skin and/or slimming the figure, comprising the application of the composition to the skin. The composition applied to the skin exhibits good cosmetic properties of softness and of non-tackiness.
Abstract: Onychomycosis present in a nail is treated by debridement such as grinding a portion of the nail, which includes an infected portion and thereafter applying a composition containing alkyl cyanoacrylate to the debrided surface which cures to a hard layer. The hard layer can be successively ground and coated with successive layers of alkyl cycanoacrylate.
Abstract: Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH2 are biologically active compounds; each X is independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone moiety), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO—, where y is 2-4 or 6-24 and —(CH2CH2O)zCH2COO—, where z is 2-24; each Y is independently selected from —COCH2O— (glycolic ester moiety), —COCH(CH3)O— (lactic ester moiety), —COCH2OCH2CH2O— (dioxanone ester moiety), —COCH2CH2CH2CH2CH2O— (caprolactone ester moiety), —CO(CH2)mO—, where m is 2-4 or 6-24 and —COCH2O(CH2CH2O)n— where n is between 2-24; R? is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.
Abstract: The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.
Type:
Grant
Filed:
June 12, 2012
Date of Patent:
April 2, 2013
Assignee:
Zalicus Pharmaceuticals Ltd.
Inventors:
Mahesh V. Padval, Jeff T. Gautschi, Daniel T. Smithey, Marshall D. Crew, Abizer Harianawala
Abstract: The present invention provides a method for preventing or repairing damage to a fetal membrane. In one embodiment, the method comprises contacting a fetal membrane with a composition comprising a four-armed catechol-terminated polyethylene glycol (cPEG) and a biocompatible oxidant. In one embodiment, the four-armed cPEG and the biocompatible oxidant are initially contained in separate solutions, and the solutions are mixed to form the composition just prior to or at the same time that the composition contacts the fetal membrane.
Type:
Grant
Filed:
July 29, 2010
Date of Patent:
April 2, 2013
Assignees:
Northwestern University, The University of Zurich
Inventors:
Phillip B. Messersmith, Carrie Brubaker, Corinne Zisch
Abstract: PEG and related polymer derivatives having weak, hydrolytically unstable linkages near the reactive end of the polymer are provided for conjugation to drugs, including proteins, enzymes, small molecules, and others. These derivatives provide a sufficient circulation period for a drug-PEG conjugate, followed by hydrolytic breakdown of the conjugate and release of the bound molecule. In some cases, drugs that demonstrate reduced activity when permanently coupled to PEG maintain a therapeutically suitable activity when coupled to a degradable PEG in accordance with the invention. The PEG derivatives of the invention can be used to impart improved water solubility, increased size, a slower rate of kidney clearance, and reduced immunogenicity to a conjugate formed by attachment thereto. Controlled hydrolytic release of the bound molecule into an aqueous environment can then enhance the drug's delivery profile by providing a delivery system which employs such polymers and utilizes the teachings provided herein.
Abstract: An anhydrous topical scar treatment product having a water activity of less than 0.50, the product being comprised of (i) a silicone elastomer, (ii) a non-volatile, anhydrous carrier vehicle, (iii) L-ascorbic acid in the form of fine powder, at a concentration of concentration of from 7.5% to 15% by weight, based on the total weight of the anhydrous topical scar treatment product, and (iv) an oil-soluble Vitamin C derivative at a concentration of from 5% to 10% by weight, based on the total weight of the anhydrous topical scar treatment product.
Type:
Grant
Filed:
January 8, 2011
Date of Patent:
March 19, 2013
Assignee:
C & H Scientific, LLC
Inventors:
Minas Chrysopoulo, Roland Hoffman, Susan Goldsberry
Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
Type:
Grant
Filed:
November 30, 2007
Date of Patent:
March 12, 2013
Assignee:
Nektar Therapeutics
Inventors:
Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
Abstract: The invention relates to a cosmetic composition of rinse-off mask type for the care of the skin, characterized in that it comprises at least one superabsorbent polymer or copolymer of water-retaining type, in the form of particles in the substantially completely hydrated state, said particles having, in the dry or nonhydrated state, a mean particle size of between 5 and 100 ?m, advantageously between 20 and 50 ?m, in particular between 20 and 30 ?m.
Abstract: The invention describes substrates, such as prosthetics, films, nonwovens, meshes, etc. that are treated with a bioadhesive. The bioadhesive includes polymeric substances that have phenyl moieties with at least two hydroxyl groups. The bioadhesive constructs can be used to treat and repair, for example, hernias and damaged tendons.
Type:
Grant
Filed:
September 28, 2009
Date of Patent:
February 26, 2013
Assignee:
KNC NER Acquisition Sub, Inc.
Inventors:
Bruce P. Lee, Laura Vollenweider, John L. Murphy, Fangmin Xu, Jeffrey L. Dalsin, Jeanne Virosco, William Lew, Jed White
Abstract: Packaging using Gas Permeable Non-Woven Fabric based Film extends the shelf life and vase life of fresh cut flowers by changing the atmosphere in which these living products are stored and respires. The high oxygen and carbon dioxide permeability of the Gas Permeable Non-Woven Fabric based Film establishes an ideal atmosphere for the cut flowers, and therefore extends its shelf life and vase life. The establishment of lower oxygen and carbon dioxide atmospheres inside packages using Gas Permeable Non-Woven Fabric based film, also leads to reduction in the respiration rate of the cut flowers. The reduction in the respiration rate prevents loss of moisture, production of metabolic heat, and yellowing, browning, reduction in production levels of ethylene. Thus the created atmosphere is able to extend shelf life, maintain high quality and preserve nutrients of cut flowers items by naturally regulating respiration of said flower.
Abstract: Coatings for implantable medical devices comprising non-fouling moieties or polymers chemically bonded to the surface of the device via chelating structures, and methods of fabricating the coatings are disclosed.
Abstract: In a first aspect, the present invention relates to a method for prevention or treating memory impairment and/or a neurodegenerative condition, disorder or disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound targeting a miRNA or any precursor, or targeting the activity of said miRNA or any precursor thereof. In particular, the present invention relates to a method wherein the targeted miRNA is miR-34. Moreover, the present invention relates to a method for improving memory functionality in a subject suffering from memory loss, said method comprises the reduction or reducing the level of miR-34 levels or precursor molecule levels in brain tissue of said subject administering to the subject a therapeutically effective amount of a compound targeting miR-34 or any precursor thereof.
Type:
Application
Filed:
July 29, 2011
Publication date:
January 31, 2013
Inventors:
Andre Fischer, Athanasios Zovoilis, Hope Agbemenyah
Abstract: One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.
Type:
Grant
Filed:
April 27, 2006
Date of Patent:
January 29, 2013
Assignees:
Pluromed, Inc., The General Hospital Corporation
Inventors:
W. Scott McDougal, Dianne E. Sacco, Alexander Schwarz, Jean-Marie Vogel
Abstract: The invention provides medical devices that comprise an iodinated polymer and that can be viewed using X-Ray imaging techniques. The invention also provides novel iodinated polymers that can be incorporated into or coated on medical devices.
Type:
Grant
Filed:
June 6, 2007
Date of Patent:
January 29, 2013
Assignee:
Rutgers, The State University of New Jersey
Abstract: One aspect of the invention relates to a hydrogel comprising a polymer comprising a plurality of pendent hydroxyl groups, a crosslinker, and a sclerosing agent. Another aspect of the invention relates to a method for reducing lung volume in a patient comprising the steps of advancing into a region of a patient's lung via said patient's trachea a multi-lumen catheter lumen through a bronchoscope; and co-administering, through the multi-lumen catheter, a first mixture comprising a first amount of a polymer containing a plurality of pendent hydroxyl groups; a second mixture comprising a second amount of a crosslinker; and a third mixture comprising a third amount of a sclerosing agent; thereby forming a hydrogel in said region. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema of the lung.
Type:
Grant
Filed:
September 27, 2007
Date of Patent:
January 29, 2013
Assignee:
Aeris Therapeutics, Inc.
Inventors:
Edward P. Ingenito, Alexander Schwarz, Larry W. Tsai
Abstract: The present invention discloses a magnetic nanomedicine for inhibiting/treating human prostate cancer, which comprises a core containing a magnetic particle having a diameter of less than 10 nm; a shell made of a carboxylated polyaniline and encapsulating the core; and a medicine covalently linked to the shell and able to inhibit/treat prostate cancer. The magnetic nanomedicine of the present invention not only has superior thermal stability and but also has water solubility higher than that of the conventional anti-prostate cancer medicine. Further, the magnetic nanomedicine of the present invention can be magnetically conducted to the cancer area to increase the local concentration of medicine and enhance the therapeutic effect.
Abstract: The present invention provides heterocyclic derivatives of formula (I) that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
Type:
Application
Filed:
October 1, 2010
Publication date:
January 10, 2013
Applicants:
XENON PHARMACEUTICALS INC., NOVARTIS AG
Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Type:
Grant
Filed:
June 29, 2009
Date of Patent:
January 8, 2013
Assignees:
Otonomy, Inc., The Regents of the University of California
Inventors:
Jay Lichter, Andrew M. Trammel, Jeffrey P. Harris, Carl Lebel, Fabrice Piu, Qiang Ye, Luis A. Dellamary
Abstract: A pharmaceutically-active polymeric compound of the general formula (I), Y-[Yn-LINK B-X]m-LINK B??(I) wherein (i) X is a coupled biological coupling agent of the general formula (II) Bio-LINK A-Bio??(II) wherein Bio is a biologically active agent fragment or precursor thereof linked to LINK A through a hydrolysable covalent bond; and LINK A is a coupled central flexible linear first segment of <2000 theoretical molecular weight linked to each of said Bio fragments; (ii) Y is LINK B-OLIGO; wherein (a) LINK B is a coupled second segment linking one OLIGO to another OLIGO and an OLIGO to X or precursor thereof; and (b) OLIGO is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; (iii) m is 1-40; and (iv) n is selected from 2-50. The compounds are useful as biomaterials, particularly, providing antibacterial activity in vivo.
Abstract: An alcohol- or glycol-soluble, water-insoluble, disinfectant composition and a method of using the same for disinfecting and for providing a prolonged antimicrobial property to a variety of surfaces, including skin. The composition comprises at least one alcohol or glycol and an antimicrobial polymer that is capable of imparting an antimicrobial property to a surface without the use of a metal or a metal-containing compound. The composition is applied to a surface and allowed to evaporate leaving a coating of antimicrobial polymer. Alternatively, the composition is incorporated into or within the substrate.
Type:
Grant
Filed:
January 8, 2009
Date of Patent:
January 1, 2013
Assignee:
Quick-Med Technologies, Inc.
Inventors:
William Toreki, Gerald Olderman, Rustom S. Kanga
Abstract: The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing with low heat generation to form materials suitable for use in scaffolds in tissue engineering applications such as bone and cartilage repair. The polymers are desirably flowable and injectable and can support living biological components to aid in the healing process. They may be cured ex-vivo for invasive surgical repair methods, or alternatively utilized for relatively non-invasive surgical repair methods such as by arthroscope. The invention also relates to prepolymers useful in the preparation of the polymeric compositions, and to methods of treatment of damaged tissue using the polymers of the invention.
Type:
Grant
Filed:
July 23, 2003
Date of Patent:
January 1, 2013
Assignee:
Polynovo Biomaterials PTY Limited
Inventors:
Raju Adhikari, Pathiraja A. Gunatillake
Abstract: A wound closure apparatus and associated methods are provided which utilize blood fluid by activating the clotting cascade of blood fluid within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. An apparatus for providing ways of inhibiting anticoagulating agents and slowing fibrin clot degradation are also disclosed. Kits are also disclosed. The invention provides a clotting cascade initiation apparatus including a substantially enclosed sterile containment chamber within which an aliquot of blood fluid, either autologous or from donor sources, can be received and retained. In preferred embodiments, the sterile containment chamber further includes a heparin binding agent which will bind heparin and remove it from the blood fluid. In further embodiments, the containment chamber will also include a procoagulating agent, wherein a clotting cascade can be initiated when the blood fluid is accepted into the sterile containment chamber.
Type:
Grant
Filed:
October 29, 2010
Date of Patent:
January 1, 2013
Assignee:
Closys Corporation
Inventors:
Karol L. Nowakowski, James E. Olson, Edward T. Joseph, Daniel G. Ericson
Abstract: The invention provides methods for making copolymers and multi-arm block copolymers useful as drug delivery vehicles. The multi-arm block copolymers comprise a central core molecule, such as a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region. The solubility of hydrophobic biologically active agents can be improved by entrapment within the hydrophobic core region of the block copolymer. The invention further includes pharmaceutical compositions including such block copolymers, pharmaceutical compositions, and methods of using the block copolymers as drug delivery vehicles.
Abstract: The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 80% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.
Abstract: Various compositions that include a hydrophobic compound and a polyamino acid conjugate are prepared. The compositions described herein are useful for a variety of drug, biomolecule, and imaging agent delivery applications.
Type:
Grant
Filed:
May 18, 2012
Date of Patent:
December 11, 2012
Assignee:
Nitto Denko Corporation
Inventors:
Sang Van, Yucheng Song, Xinghe Wang, Zheng Hou, Zhongling Feng, Gang Zhao, Lei Yu
Abstract: [Problems] To provide a novel taxane derivative which can release the medicinal substance in a bioenzyme-independent manner, is expected to have an effective therapeutic efficacy, and has a water-solubility. [Means for Solving Problems] Disclosed is a polymer conjugate of a taxane, which comprises a polymer having a polyethylene glycol moiety and two or more succinic acid monoamide moieties and a taxane, wherein a carboxylate group in the polymer and an alcoholic hydroxyl group in the taxane are bound to each other via an ester bonding.
Type:
Grant
Filed:
March 22, 2007
Date of Patent:
December 4, 2012
Assignee:
Nippon Kayaku Kabushiki Kaisha
Inventors:
Masayuki Kitagawa, Keizou Ishikawa, Takeshi Onda
Abstract: A biocide composition, comprising 2-methylisothiazolin-3-one as a biocidal active ingredient and at least one further biocidal active ingredient, as an additive to materials capable of being attacked by harmful microorganisms, wherein the composition comprises a pyrithione as the further biocidal active ingredient.
Type:
Grant
Filed:
January 12, 2009
Date of Patent:
December 4, 2012
Assignee:
Thor GmbH
Inventors:
Dagmar Antoni-Zimmermann, Rudiger Baum, Hans-Jurgen Schmidt, Thomas Wunder
Abstract: The invention provides a multi-arm block copolymer for use in delivering a variety of bioactive agents. The copolymer of the invention contains a central core from which extend multiple (3 or more) copolymer arms. Each copolymer arm possesses an inner polypeptide segment and an outer hydrophilic polymer segment. Thus, the overall structure of the copolymer comprises an inner core region that includes the central core and the inner polypeptide segment, while the outer core region is hydrophilic in nature. The multi-arm copolymer of the invention is particularly useful for delivery of biologically active agents that can be entrapped within the inner core region.
Abstract: An antimicrobial paper includes a paper web having a grammage between 10 and 60 grams per square meter, a cationizing agent in a concentration ranging between 0.05 wt % and 5 wt %, an antimicrobial agent in a concentration ranging between 0.01 wt % and 3 wt %, the antimicrobial agent and the cationizing agent being added on the paper web having a consistency above 15 wt %, the antimicrobial paper having an antimicrobial agent release of above about 0.01 wt % when wetted.
Type:
Application
Filed:
January 18, 2011
Publication date:
November 29, 2012
Applicant:
CASCADES CANADA ULC
Inventors:
Marie-Hélène Charest, Jean-Francois Samuel, Pascal Allard, Régis Arsenault, Charles Beaulne, Jean-Marc Bouchard, BenoiT Graton, Gabriel Sanapo
Abstract: Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH2CH2— group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.
Type:
Application
Filed:
November 1, 2011
Publication date:
November 15, 2012
Applicant:
Genzyme Corporation
Inventors:
Chad C. Huval, Stephen Randall Holmes-Farley, Pradeep K. Dhal
Abstract: The invention relates to the use of polymeric or oligomeric active ingredients having a biocidal effect as additives in the composition of medical articles. The invention further relates to medical articles that comprise such additives.
Type:
Application
Filed:
November 12, 2010
Publication date:
November 8, 2012
Applicant:
B. BRAUN MELSUNGEN AG
Inventors:
André Weiss, Thomas Riemann, Martin Sippel
Abstract: The present invention relates to an ampholytic copolymer based on quaternized nitrogen-containing monomers which has a molar excess of cationogenic/cationic groups compared to anionogenic/anionic groups, to cosmetic or pharmaceutical compositions which comprise at least one such ampholytic copolymer, and to further uses of these copolymers.
Type:
Grant
Filed:
September 14, 2007
Date of Patent:
November 6, 2012
Assignee:
BASF SE
Inventors:
Son Nguyen Kim, Axel Jentzsch, Nathalie Bouillo
Abstract: The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.
Abstract: A novel class of mixed micelles formed with critical micelle concentration (Cmc) character's diblock copolymer, and temperature-sensitive character's diblock copolymer were disclosed. The mixed micelles possess complementary effects in adjusting external temperature shift (storage vs. body temperature) and concentration change (dilution after intravenous injection). The mixed micelles of the present invention can serve as a potential injectable drug delivery system for anticancer drugs, such as doxorubicin and many others.
Abstract: Cosmetic composition which can be applied topically, comprising at least one compound of the general formula (I) in which R1 is H, C1-C20-alkyl, cycloalkyl or aryl-C1-C4-alkyl, n is 1-4, X is —O—, —NH— or —NR2— and R2H or C1-C20-alkyl; and at least one compound corresponding to the above formula (I) but in which XR1 with X having the possible meaning of —NH— is the residue of an alpha-amino acid; use of these compounds and of the composition for stimulating the synthesis of the proteins of the basement membrane; and also both those compounds of the formula (I) in which X is —NR2— and both R1 and R2 are different from H, and the compounds corresponding to formula (I) but in which XR1 with X having the possible meaning of —NH— is the residue of an alpha-amino acid, as such.
Type:
Grant
Filed:
April 28, 2006
Date of Patent:
October 23, 2012
Assignee:
DSM IP Assets B.V.
Inventors:
Hugo Ziegler, Dominik Imfeld, Martin Stöckli, Marc Heidl
Abstract: A composition for cosmetic preparation and a cosmetic preparation including the composition are provided. The composition includes a silicone-modified wax having a melting point of 100° C. or above and an unctuous agent having a melting point of 80° C. or below. The composition is prepared by cooling after dissolving and mixing the silicone-modified wax and the unctuous agent at temperature equal to or higher than the melting point of the silicone-modified wax. The composition has a smooth feel and a glossy surface and can be blended in a cosmetic preparation without being heated at 100° C. or above.